Skip to main content

INEOS Donation Helps Fight Antimicrobial Resistance

INEOS joins forces with Oxford University, creating a state-of-the-art institute to fight ���silent pandemic���.

A ��100m donation by INEOS will create a new, world-leading antimicrobial research facility at Oxford University.

Antimicrobial resistance (AMR) is an ever-growing global problem, which is currently responsible for an estimated 1.5 million excess deaths every year. This is a figure that could increase to 10 million by 2050, by which time the economic toll could reach $100 trillion.

As the world fast runs out of effective antibiotics, the new INEOS Oxford Institute will be dedicated to developing new drugs and preventing the ���superbugs��� that make even simple procedures dangerous.

Sir Jim Ratcliffe, Chairman of INEOS, said: ���Innovative collaboration between industry, academia and government is now crucial to fight against AMR. INEOS in its 22 years has become the largest private company in the UK, delivering large-scale, ambitious technical projects with impactful results. We are excited to partner with one of the world���s leading research universities to accelerate progress in tackling this urgent global challenge.���

Professor Louise Richardson, Vice Chancellor of the University of Oxford, said: ���This is a wonderfully generous gift for which we are very grateful. It is another example of a powerful partnership between public and private institutions to address global problems. Oxford played a crucial role in the early development of antibiotics so it is only appropriate that we take the lead in developing a solution to antimicrobial resistance.���

By making one of the largest ever donations to a UK university, INEOS has committed to fighting the greatest healthcare and economic challenge facing the post-Covid world, continuing its long history of philanthropy in public health.